Drug reference
cyclopentolate
Muscarinic antagonist · Anticholinergic
Muscarinic antagonistAnticholinergic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Not yet extracted
Indications
Ophthalmological examination (cycloplegia and mydriasis induction)cycloplegiamydriasisuveitisCycloplegic refractionIritis
Pharmacokinetics
Onset
mydriasis and cycloplegia occur in 30–60 min
Duration
Shorter duration of action than atropine
Side effects
Common
Transient behavioural abnormalities in children (due to absorption of the drug after passage into the nasolacrimal duct)
Related guidelines
Other Muscarinic antagonist drugs
Ask House about cyclopentolate
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team